Capital Performance Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Capital Performance Advisors’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.6K	Buy	+14,756	New	+$25.8K	﹤0.01%	465

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Capital Performance Advisors's MIST Position: Q1 2026 in Review

Capital Performance Advisors opened a new position in Milestone Pharmaceuticals (MIST) in Q1 2026: 14,756 shares worth $17.6K. The stake represents ﹤0.01% of the portfolio and ranks #465 among its holdings.

86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

Capital Performance Advisors held 14,756 shares of Milestone Pharmaceuticals worth $17.6K as of Q1 2026.
Milestone Pharmaceuticals was a new Capital Performance Advisors position in Q1 2026.
Milestone Pharmaceuticals made up ﹤0.01% of Capital Performance Advisors's portfolio in Q1 2026, its #465 holding.
86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Capital Performance Advisors's 13F filing for Q1 2026, filed 7 May 2026.